Clinical Trial

Test of Ankylosing Spondylitis Drug in Healthy Subjects

Study Description

Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis

This study is intended to treat ankylosing spondylitis (AS). AS is a form of arthritis that primarily affects the spine. It is characterized by inflammation of the spinal joints that can lead to severe pain, and in more advanced cases, ankylosis (sections of the spine fuse in a fixed, immobile position). The study will be an ascending single and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous KIN-1901 in healthy subjects and subjects with AS.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - KIN-1901

KIN-1901 is a fully human monoclonal antibody (mAb).

Drug - Placebo

Saline

Additional Information

Official Study Title

An Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Gimsilumab in Healthy Subjects and Subjects With Ankylosing Spondylitis

Clinical Trial ID

NCT04205851

ParticipAid ID

b82jle